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Abstract 
 
Although patent data have severe limitations as a measure of technological innovation 
(Griliches, 1990), patent data are frequently used for this purpose, providing potentially 
misleading analyses for policy makers. Kingston and Scally (2006) have shown that, for 
countries outside the NAFTA region, USPTO small enterprise patent data can provide 
useful insights into innovative activity in small and medium sized economies. This 
exploratory analysis investigates whether the Kingston/Scally analysis can be extended 
from inventors to assignee firms and considers the challenges of making this conversion. It 
also explores whether such a data series can be used to develop a typology of innovating 
firms which can be of interest for research and policy analysis purposes. 
 
Australian inventor granted patent data from the USPTO BIB series from 1969 to 2010 is 
used to explore these issues. The focus is on patents assigned to firms. Converting these 
data to a set based on the residence of the firm owning the patent is tedious but not difficult. 
Nonetheless given the importance for policy purposes of focusing on innovative firms, it 
would be very useful if the USPTO were to include the assignee residence in the BIB 
dataset. More challenging, of course, is trying to ensure identification of all patents owned 
by any one firm. Typographical errors, keying errors and name changes make this a 
particularly tedious issue. It would be helpful if patent offices were to require (and use) a 
firm’s company number as the principle identifier for data on a patent. In addition there are 
problems arising from changes in firm ownership and how these should be treated. 
 
Three principal groupings of firms stand out – those which patent only once (the large 
majority); Silverbrook, with a portfolio of thousands of US patents; and some 400 firms 
with at least several US patents granted since 1995. A discussion of those firms with 
significant US patent holdings shows a variety of types of innovation leadership.  
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1. The Issues 
The limitations of using patent data as a measure of technological innovation have long 
been known (Griliches, 1990). Despite this, patent data are frequently used in this way, 
providing potentially misleading analyses for policy makers. Kingston and Scally (2006) 
suggest that, for countries other than the USA, Canada and Mexico, USPTO small 
enterprise data can provide a potentially more valid approach to identifying genuine 
innovative activity in small and medium sized economies. This exploratory analysis, using 
data for Australia, investigates whether the Kingston/Scally analysis can be extended from 
inventors to assignee firms and considers the challenges of making this conversion. It also 
explores whether such a data set can be used to develop insights into innovating firms 
which can be of interest for research and policy analysis purposes.  
The paper starts with a discussion of a range of issues in converting these data from an 
inventor basis to a firm ownership basis – a perspective that is more useful for innovation 
policy purposes (Section 2). This discussion identifies some aspects of patent data that 
could be improved to increase their value to policy makers. In Section 3 the characteristics 
of Australian firms patenting in the USA are explored, suggesting considerable differences 
in firms’ use and experience of US patenting. This discussion identifies further data issues 
in analysing the patent data on a firm basis for a particular country.  
Given these data issues is it possible to use these data for any meaningful analysis of 
innovative firms in a particular economy? This question is addressed in Section 4. A variety 
of types of firms are frequent US patenters – some are examples of technology spinouts 
from scientific research; others began as foreign subsidiaries; some have been taken over 
by overseas companies; and some work in product areas not generally considered to be very 
high technology. Overall however, the insights that can be gained from patent data alone 
are limited. Conclusions are presented in Section 5.  
2. Methodology 
As the largest single market in the world, data on patent activity in the USA by innovating 
firms should, for many countries, provide useful information into domestic firms with 
globally-directed innovative activity.1 A further reason for using data for the USA is that, of 
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 That is, the patent data act as a proxy for selling into the USA, not for inventiveness. The low standard of the 
US patent inventive step is well documented, so US patents cannot in general be taken as a proxy for 
inventiveness (see e.g. Jaffe & Lerner, 2004, Lunney, 2001).  
2 
all major national patent offices, the United States Patent and Trademark Office (USPTO) 
provides the most accessible data for research purposes. The one downside of this dataset is 
that data on the geographic ‘home’ of granted patents is provided on the basis of the 
inventor not the owner of the patent. 
The initial dataset, extracted from the USPTO “Patents BIB” series,2 consists of all patents 
granted from 1969 to 2010 where any inventor reports Australia as their country of 
residence. This dataset of 23,833 cases,3 was reduced to the sub-set where the patent was 
assigned to any organization or firm, excluding non-profit entities (16,545 cases). Data on 
the country of the assignee firm were then added to the dataset.  
2.1 Identifying all patents owned by each firm 
Following this, substantial work was undertaken to identify all the US patents owned by a 
single firm. Small differences in how a company name is entered, together with 
typographical errors, can mean considerable work in checking company identity. Because 
there is only limited bibliographic information on the scanned record, sometimes this 
information is inadequate to identify if, for example, two particular patents are owned by 
the same company or by different companies with very similar names. Information used in 
this matching process included inventor names, residence of assignee in the USPTO 
records, similarity in patent titles, independent information from the ASIC company search 
website,4 information on companies listed on the Australian Securities Exchange,5 ceased 
or suspended companies from the deListed website6 and general web searches.7  
In many dealings with governments firms are required to provide a company registration 
number or other formal identifier. If such a requirement were added to the patent monopoly 
system, researchers could more readily analyse firm ownership of patents. This could also 
provide a very valuable additional source of data on innovative firms as national statistical 
offices can use such identifiers to cross-link firm data acquired through different surveys. 
This would provide valuable insights into the use of the patenting system by innovative 
firms.  
A further challenge is that companies can take many separate corporate identities, even 
where each subsidiary is 100 percent owned. These complex corporate structures provide 
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 http://www.uspto.gov/products/catalog/patent_products/page6.jsp#heading-5 (“Patents BIB: Selected 
Bibliographic Information from US Patent Grant Publications and Patent Application Publications 1969 to 
Present”). The version used provides data on all grants to the end of 2010.  
3
 The initial dataset was 23,836 cases but two very old cases were discarded (one filed in 1930 and one in 
1938). A third case was deleted as it involved an Austrian inventor and assignee, misclassified as AU not AT.  
4
 The Australian Securities & Investments Commission (ASIC) maintains the official register of all Australian 
company names and this can be searched at http://www.search.asic.gov.au/gns001.html . 
5
 The Australian Securities Exchange (ASX) website provides a useful look-up service for listed companies at 
http://www.asx.com.au/research/company-research.htm . 
6
 “deListed provides updates and information on failed companies including those in external administration 
and companies suspended from ASX, NZX, NSX and BSX. It also has all historical name changes and 
delistings for these exchanges and carries administrators/liquidators declarations for Australian companies for 
tax purposes” (http://www.delisted.com.au/aboutus.aspx).  
7
 The latter are considerably hampered by many aggregator companies selling company information services. 
Annoyingly, most such companies provide no information beyond the company name, so they impede rather 
than facilitate web search. For smaller companies this can mean considerable difficulty in actually finding the 
company website, and there are some challenges even for some larger companies.  
3 
major legal and financial benefits to owners. But such legal fictions are irrelevant where the 
issue of interest is patent ownership and the impact of ownership on firm behaviour. There 
is thus a need to delve behind the ‘corporate veil’ to re-assign patents owned by separate 
elements within a corporate grouping to the current final owner. This raises challenges – at 
what point in time should such ownership be determined? One of the alleged purposes of 
the patent system is to facilitate trade in technology, often through the purchase of 
innovative start-up companies. In a sense therefore re-assignment to the new owner merely 
follows the original intent of the development of the new technology – to acquire a 
financial return through selling the company. Here efforts have been made to reassign 
ownership to the current owner.8  
2.1 Determining firm ‘nationality’ 
The next issue is determining when company residence can be classified as Australian. For 
a large majority of companies this is straightforward as all their patents are linked to an 
assignee company resident in Australia. But 1,187 firms assigned all patents in the dataset 
to entities resident only outside Australia and 97 other firms assigned some of their patents 
to entities outside Australia. The official USPTO definition of inventor residence is 
residence at grant, which could be seven or more years after the application is filed.9 In 
practice at least some of the inventor residence data is collected at the time of application.10  
If inventor residence data were consistently as at grant, there is substantial opportunity for 
the inventor to move between invention and grant. Using the somewhat crude measure of 
year of issue less year of filing, some 18 percent of patents were granted within a year and a 
further 35 percent in the second year – plenty of opportunity for the inventor to change 
residence. The data in Table 1 show that where there is any overseas assignment by the 
firm a higher proportion of patents are granted after a more substantial time lag – 19 
percent are granted after a delay of five or more years (compared to 13 percent among firms 
where all assignment is to Australian entities).  
Table 1 Assignment of patents by gap between years of application and grant 
 Assignment of US patents with Australian inventors 
Difference between 
patent issue year 
and file year 
All assigned 
overseas 
Some 
assigned 
overseas 
Any assigned 
overseas 
All 
assigned in 
Australia 
Same year 1% 0% 1% 1% 
1 year 14% 14% 14% 18% 
2 years 32% 31% 32% 37% 
3 years 21% 22% 21% 22% 
4 years 14% 14% 14% 11% 
5+ years 19% 19% 19% 13% 
Total 100% 100% 100% 100% 
N 3,521 2,101 5,622 10,923 
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 Research funds did not permit access to commercial company databases, so this effort is incomplete. 
9
 “Inventor Country (ICN): This field contains the country of residence of the inventor at the time of patent 
issue.” (http://www.uspto.gov/patft/help/helpflds.htm#Inventor_Country).  
10
  Personal communication from USPTO. 
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From a policy perspective inventor residence at filing would be more useful – the file year 
reflects both the closest point to actual inventive activity and the time when the initial 
business decision to seek a patent monopoly is made. Inventor residence at time of grant 
might be useful in the grant year, but such data will age in a way that file year data will not. 
The unknown mixture of timing for inventor residence complicates assessing the 
implications of Australian-invented US patents assigned to non-Australian entities. Where 
these patents involve a delayed grant, and the applicant has provided inventor residence at 
time of grant, then the patent may have nothing to do with Australia, in terms of the 
location of R&D activity.  
On the other hand, the inventive activity may have occurred in Australia but the firm may 
have a policy of assigning all patents to corporate headquarters. Of the 477 firms in this 
category with two or more US patents, all but 32 assign all patents to a single country. Only 
a few companies assign patents to entities in more than one country, for example, Nokia. In 
some cases assignment to more than one country is simply a product of subsequent 
corporate take-overs – for example BASF and Bayer. Another reason for mixed assignment 
is joint ownership, where R&D was undertaken cooperatively, e.g. some Biogen and 
Celerity patents.  
Within the set of 1,147 firms with 2 or more patents, and at least one assigned to an 
Australian-based entity there were 97 cases, mostly larger enterprises, where assignment 
had mixed nationality. Where a firm has multiple patents and mixed nationality assignment, 
there is a challenge in assigning an overall nationality to the firm. Here this was done on the 
basis of the country to which patents are most frequently assigned, except where there was 
clear alternative information about company headquarters. In some cases determining 
companies’ nationality is uncertain – for example if only two US patents are owned and 
one is assigned in Australia and one overseas.  
Mixed assignment by overseas companies 
Twenty-four overseas-based companies with over ten Australian-invented US patents 
assign only some of these patents to Australian entities (Table 2). Generally the large 
majority are assigned back to the home base, with the apparent exception of Alcatel simply 
being due to takeover activity. The interesting cases are those with a smaller share of 
patents assigned overseas. For example, Ishikawajima-Harima Heavy Industries partnered 
with Bluescope Steel for all 119 patents, all of which are jointly owned, hence the 50 
percent assignment to Australian entities. Schefenacker Vision, with only 8 percent of 
patents assigned back to the USA, has both a manufacturing and an R&D facility in South 
Australia. The original Australian company (Rainsford Metal Products Pty Ltd) was 
acquired by the British Britax International and subsequently became part of US-based 
Schefenacker Vision. The continued Australian presence may be partly reliant on 
government adjustment assistance to the automotive industry and to other programs such as 
the Export Facilitation Scheme and the R&D tax concession.  
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Table 2: Overseas-based firms with over 10 US patents and assignment to Australian 
entities 
Company Company 
head-
quarters 
Number 
US 
patents 
% 
assigned 
overseas 
Major 
assignee 
country 
% to major 
assignee 
country 
Robert Bosch DE 29 97% DE 96% 
Siemens US 28 96% US 52% 
Massey-Ferguson AN 23 96% AN 100% 
Lubrizol US 12 96% US 100% 
Nalco US 16 94% US 100% 
Borg Warner US 15 93% US 100% 
Canon JP 376 92% JP 100% 
Chiron US 20 90% US 100% 
Alcatel FR 103 89% US 51% 
Du Pont US 28 89% US 92% 
Illinois Tool Works US 19 89% US 100% 
Dow Corning US 11 82% US 100% 
Smith & Nephew US 11 82% US 100% 
Cisco US 119 81% US 100% 
Ericsson SE 63 76% SE 100% 
Sealed Air US 12 75% US 56% 
Nortel CA 11 73% CA 100% 
Johnson & Johnson US 32 72% US 96% 
ABB CH 15 70% CH 76% 
Sandvik SE 16 69% SE 82% 
Ishikawajima Harima JP/AU 51 50% JP 100% 
Glaxo GB 17 47% US 63% 
Rib Loc HK 16 38% HK 100% 
Schefenacker Vision US 37 8% US 100% 
Notes: See Appendix for a list of patent country codes. 
Glaxo’s assignment of nine of its 17 patents to an Australian entity stands in sharp contrast 
to other major pharmaceutical companies which assign all their Australian-invented US 
patents to their home base (Novartis, Pfizer, Hoffmann-La Roche, for example). Despite 
extensive Australian government support to the pharmaceutical industry there are no major 
players undertaking R&D in and assigning US patents to Australian entities, except for a 
small number of indigenous success stories which are discussed below (Section 3.4).   
Rib Loc is an entirely different story – this is an Australian pipe manufacturer which 
became a target of interest to a Hong Kong based investment company, Chevalier, who 
launched a take-over bid in 2004. Rib Loc is now one of its brands, but remains based in 
Australia.11  
Mixed assignment by Australian companies 
On the basis of the share of patents assigned to Australian entities 11 companies with 
mixed assignment of ownership and more than ten US patents were initially classified as 
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 See http://www.chevalier.com/english/contentpage.asp?id=1170 and http://www.theage.com.au/articles/ 
2004/02/25/1077676832013.html?from=storyrhs  
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Australian-based (Table 3). On further scrutiny it becomes clear that most are in fact head-
quartered overseas. US-based Agilent acquired Varian in 201012 and most of the patents in 
the dataset are owned by Varian entities either in the USA or in Australia.13 Dilithium and 
the Cook Group are also US-based while the Leica brand covers three companies based in 
Germany and Switzerland. Carl Zeiss Vision is also US based and owns, among other 
companies, Sola Lenses. This was originally a leading edge Australian contact lense 
manufacturer, Sola standing for Scientific Optical Laboratories of Australia, incorporated in 
1960 in Adelaide. It was acquired by Pilkington PLC and then spun out in 1993 before 
being acquired by Carl Zeiss in 2004.14 All but three of Carl Zeiss’ 49 US patents are 
assigned to Sola International Holdings Ltd. While Australian production operations have 
been wound back, Sola still undertakes at least some R&D in Adelaide.15 
Table 3: ‘Australian’ firms with over 10 US patents, some assigned overseas  
Company Company 
nationality 
Number 
of US 
patents 
% 
assigned 
overseas 
Major 
assignee 
country 
% to major 
assignee 
country 
Agilent (Varian) US 57 46% US 100% 
James Hardie AU  NL IE 44 41% NL 61% 
Leica DE/CH 11 36% CH 75% 
Dilithium US 22 27% US 100% 
Cook Group US 31 26% US 63% 
BOC gases GB  DE 42 21% US 89% 
Orica  GB  AU 265 12% GB 100% 
Memtec AU  US 34 12% US 100% 
Carl Zeiss Vision (Sola) US 49 6% US 100% 
Bluescope Steel AU 27 4% PA 100% 
BHP AU 166 1% US 50% 
 
Four of the 11 ‘Australian’ companies changed ‘residence’ over the period. Two did so 
because of take-over activity (BOC, Memtec). One company became Australian due to 
divestment by its overseas parent (Orica). A fourth company which changed ‘residence’ did 
so for strategic reasons at a time of major legal dispute over occupational health liabilities 
(James Hardie). What impact will these changes have on the apparent residence of patent 
ownership? For Orica most patents were assigned to the Australian-based entity prior to 
this corporate change, so there is likely to be a small shift to 100 per cent assignment to 
Australia. Before James Hardie’s corporate move all US patents were assigned to an 
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 http://www.home.agilent.com/agilent/home.jspx?cc=US&lc=eng  
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 Varian was founded in the late 1940s by scientists associated with Stanford University. Varian now 
employs some 5,500 people in oncology treatment equipment, x-ray tubes and the use of x-rays for security 
screening. Within Australia Varian focuses on oncology-related measuring equipment 
(http://www.varian.com/us/corporate/our_company/company_facts_history.html).  
14
 http://www.fundinguniverse.com/company-histories/Sola-International-Inc-Company-History.html 
15
 A press release of 5 March 2009 refers to a grant “through the South Australian Innovation and Investment 
Fund which will be used to expand operations in the cutting-edge free-form surfacing division” (see 
http://www.vision.zeiss.com.au/C12571C3003240A9/EmbedTitelIntern/PR_CZV_Future/$File/CZV_Prepare
s_Way_to_Future.pdf). 
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Australian entity. Since 2005 all have been assigned to Ireland, and in between there was 
mixed assignment to Australia, the Netherlands and Ireland. It seems likely that all future 
US patents will be assigned to the new Irish headquarters. Before being taken over in 2006 
by the German Linde group, most of BOC’s 42 Australian-invented US patents were 
assigned to the Australian subsidiary, with the bulk of those assigned overseas assigned to a 
US subsidiary. There is as yet no clear indication of what Linde’s patent assignment policy 
will be. Memtec began assigning patents to its new US subsidiary in 1995, and was 
subsequently purchased by US-based Pall Corporation. No Australian-invented US patents 
have been granted from filings since mid 1996 suggesting that the Sydney R&D expertise 
has either moved to the new US venue or has been disbanded. 
The remaining two companies are, like Orica, Australian-based. But the proportion of their 
patents assigned overseas is very small. Only one of Bluescope’s 27 patents is assigned 
overseas – to Panama – and only two of BHP’s 166 patents are assigned overseas.  
Overall 35 percent of firms in the dataset assign all their Australian-invented US patents to 
non-Australian firms and a further 3 percent of firms assign some of their patents overseas. 
The dominant countries where Australian-invented patents are assigned overseas are the 
USA, the UK and Germany. A small point of interest is that there are 13 tax haven 
countries among those where these patents are assigned, though the number of patents 
involved is small (51). But clearly the majority of Australian-invented US patents are 
assigned to Australian entities (Figure 1).  
Overseas assignment of patents thus means that close to 30 per cent of Australian-invented 
US patents are not owned by Australian-based entities. Doubtless this is offset to some 
extent by US patents invented by residents of other countries but owned by Australian 
firms. It does, however, seem likely that the actual R&D effort for many of these overseas 
owned patents occurred in Australia.  
Figure 1: Assignment of US patents owned by firms and invented by Australian 
residents, 1970-2010 
all patents for firm
assigned overseas
o'seas share where firm
has mixed assignment
AU share where firm has
mixed assignment
no patents for firms
assigned overseas
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3. Basic characteristics of the dataset 
A number of characteristics of firms in this dataset can be explored to understand what 
types of firms are patenting in this major overseas market: number of US patents owned, 
the time period in which such patenting activity is carried out, whether the firms claim the 
small entity fee, whether patents are assigned to any entities resident outside Australia and 
the technology field in which they operate. Most of this analysis is based on the dataset of 
13,024 patents owned by 3,401 firms where at least one patent held by a firm is assigned to 
an Australian entity. 
3.1 Volume of patents owned  
It is well known that both patent ownership and returns from patent ownership are highly 
skewed distributions. The 13,024 patents in the dataset are owned by 3,401 firms, of which 
2,256 have only one US patent each during the 42 year period covered by the data. Within 
the remaining 1,145 firms patent ownership is highly skewed – at one extreme 548 firms 
have only 2 patents. At the other extreme one firm, Silverbrook Research Pty Ltd owns 
3,666 US patents filed between 1998 and 2010. Figure 2 shows the distribution of patents 
owned by all 3,401 firms, while Figure 3 shows the distribution excluding both Silverbrook 
and all firms with 10 or fewer patents. Figure 3 thus focuses on 100 of the firms in the 
extreme bottom left corner of Figure 2. 
 
Figure 2:   
Australian firms owning US patents: 
1969-2010, by US patents held. 
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Figure 3:   
Australian firms with 51-400 US patents 
owning US patents: 1969-2010. 
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An alternative way of looking at these data is to consider the number of firms with 
different levels of US patenting activity (Figure 4). While Silverbrook dominates the 
number of patents held, it is the sole firm patenting at this volume. The next most prolific 
patenter holds 376 US patents. Indeed there are only 15 other firms with more than 50 US 
patent grants.16 Of these 15 firms six assign at least some of their Australian-invented US 
patents to entities resident outside Australia. The dataset is dominated by firms who have 
only a single experience of patenting in the USA – 66 percent of the firms in the dataset. 
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 Canon, Orica, Resmed, BHP, Orbital, Cisco, Technological Resources, Cochlear, Aristocrat, Rio Tinto, 
Ericsson, Alcatel, Agilent, Bishop and Ishikawajima Harima. 
9 
A further 22 percent have only 2 or 3 US patents, and just 7 percent (224 firms) have six 
or more US patents. 
Figure 4: Australian-based firms, total number of US patents held. 
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3.2 Patenting behaviour over time  
Patenting behaviour changed significantly during the period 1969 to 2008 (Blind et al., 
2003, Hall, 2005, Kim & Marschke, 2004, Kortum & Lerner, 1999). This ‘explosion’ of 
patenting can be clearly seen in Figure 5 – after a long period of only gradual increase, 
there is a significant year-on-year increase from the early 1990s. The apparent decrease 
since 2004-05 is due to the fact that these are file year data not grant year data – it can 
take a number of years for a cohort of applications to be fully processed.17 For example, 
if Silverbrook’s pending applications are all be granted (as was the case for filings in 
1998, 1999, 2000 and 2002) then the series shows no general pattern of decline, as shown 
in Figure 6 below. 
These data also show the extraordinary dominance of a single firm on the series in recent 
years. Silverbrook first applied for US patents in 1998, and in all but two years since then 
has contributed at least 27 percent of all US patents held by Australian-based firms. This 
figure rises to 62 percent in 2002 when 731 Silverbrook applications were granted. If 
Silverbrook had not emerged, the series would peak earlier (2001-02 rather than in 2004) 
but at a lower level. The pattern of an increasing number of applications for US patents 
over time, followed by a fall-off, is clear for firms operating at all levels of US patenting 
activity, from firms who only ever obtain one patent to those with hundreds.  
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 The discussion below on Silverbrook shows the long delays that can occur in fully processing a cohort of 
patent applications (see Table 7).  
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Figure 5: US patents granted to Australian-based firms by 31 December 2010, by 
filing year (1970 to 2008) and total number of US patents held by firm. 
0
200
400
600
800
1000
1200
1400
1970 1975 1980 1985 1990 1995 2000 2005
1 2 or 3 4 to 10 11 or 50 51 to 400 Silverbrook# US patents:
 
Figure 6: US patents granted to Australian-based firms by 31 December 2010, by 
filing year (1970 to 2008), assuming all pending Silverbrook patents granted. 
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Silverbrook illustrates the care that must be taken in using patent statistics. While such 
strategic patenting behaviour is not unusual in the complex technology areas, especially 
electronics, if such firms are rare in an economy (as is the case in Australia) then simple 
use of overall data can be misleading. Gans and Hayes, for example, use US patent grants 
as their key measure of ‘national’ innovative output for Australia. While they note that 
Australia’s increased technological specialisation is largely due to Silverbrook (Gans & 
Hayes, 2009: 11), there is little discussion of the impact of Silverbrook on the volume of 
US patents in the period since 1998. This example also raises the question of whether the 
story told by patent statistics might differ if data on the relatively small number of very 
frequent users of the patent system were analysed separately.  
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3.3 Firm size  
In 1984 the US Congress introduced lower patent application and renewal fees for small 
enterprises and those with non-profit-making status. To be eligible for this reduced fee a 
profit-making firm has to have fewer than 500 employees. If the small enterprise (SE) fee 
is falsely claimed, the patent becomes invalid, so there is a strong incentive not to 
misclaim this benefit. Data on SE fees by patent number were provided by the USPTO to 
Kevin Scally and through him to the author. These data are not available for all cases in 
the USPTO BIB series. Among the 2,256 firms with only one US patent, 979 claimed the 
SE fee and 364 are known to have paid the full fee. This leaves 913 such firms where fee 
data do not indicate firm size. About a third of these relate to patents filed before the end 
of 1984, when the SE fee was introduced (331 of 913).  
The default assignment option for these single patent 
missing data firms is that they are small enterprises – they 
are resident in Australia, which has a relatively small 
manufacturing base and where larger firms tend to be 
well-known names. Indeed the Australian definition of a 
small business is one which employs fewer than 20 
people,18 so a firm employing 500 or more would be seen 
as quite large. For all these single patent missing cases 
assignee names were scrutinised and large enterprise 
status was assigned in only 11 cases.19 Following this, 83 
percent of firms with only one US patent are classified as 
small. Among the 364 firms not claiming the SE fee, 
scrutiny of their names suggests that in fact as few as a 
dozen might have 500 or more employees. But as 
Kingston and Scally demonstrated (2006: pp14-16), small 
firms do not always claim the SE fee, so many of these 
364 firms may in fact be small firms. 
For firms with two or more patents where size data were missing each firm name was 
searched on the ASIC, ASX and deListed websites and in the Encyclopedia of Australian 
Science which provides useful basic information on many Australian organisations, 
including companies.20 A general web search was also done. If none of these sources 
identified the company, then it was given the default value of small enterprise. If a 
company website was found this was searched for data on company size. If no clear 
evidence of size was found the company was designated as small. There were 270 cases 
where this procedure was followed to determine likely firm size. This intensive process 
also identified further firms with common ownership.  
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 http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1321.0Glossary12001?OpenDocument  
19
 John Fairfax & Sons Ltd., Brambles Holdings Ltd., Bowater-Scott Corporation Ltd., Burns, Philp & Co. 
Ltd., Ok Tedi Mining Ltd., Pak-Poy & Kneebone Pty Ltd., Broken Hill Associated, Palmer Tube Mills 
(Aust) Pty Ltd., North Broken Hill Ltd., Hoover (Australia) Pty Ltd., and the strangely named “Council of 
the Science” (likely a coding error, but the patent is jointly owned with the University of Adelaide, which 
although non-profit would be a large employer). 
20
 The Encyclopedia of Australian Science  is at http://www.eoas.info/browsea_corporatebodies.htm  
Box 1:  
Mixed SE fee strategy 
Among the 1,147 firms with 
more than one US patent, 
208 only sometimes claimed 
the SE fee. In 12 cases this 
appears to be either an error, 
or a case of firm growth. The 
remaining 196 constitute 47 
percent of small firms with 
two or more US patents. The 
practice of only sometimes 
claiming the SE fee is 
clearly common.  
12 
Because of the very high definition of ‘small’ the dataset is dominated by ‘small’ firms – 
overall 78 percent of firms. The proportion of ‘small’ firms falls over time: among firms 
who last filed a granted US application in 1984 or earlier, fully 93 percent were small 
(Table 4). However, among firms which last filed a granted patent application in 1995 or 
later only 72 percent were classed as small.21  
Another clear pattern in regard to firm size is the prevalence of small firms among those 
with fewer patents. Of those firms with only one US patent, 83 percent are small. By the 
time patent ownership reaches between six and ten US patents, only 56 percent of firms 
are small. For those owning 50 or more US patents, only 13 percent are small. The most 
voluminous US patenter in the dataset, Silverbrook Research Pty Ltd, now has more than 
500 employees. This pattern of larger firms dominating the patent system – owning the 
largest volume of patents and patenting more intensively is well documented elsewhere.22  
Table 4 Firms size by year last patented, and number of US patents granted 
 Firm Size 
Total % small 
 Small Large Dead 
Year of last filed patent* 
1969 to 1984 399 25 4 428 93% 
1985 to 1994 744 101 5 850 88% 
1995 to 2010 1519 604 0 2123 72% 
Total 2662 730 9 3401 78% 
 
     
# US patents   
1 1881 375 0 2556 83% 
2 415 129 4 548 76% 
3 150 57 1 208 72% 
4 or 5 117 47 1 165 71% 
6 to 10 68 53 0 121 56% 
11 to 50 30 54 3 87 34% 
51 to 400 1 14 0 15 7% 
* These time periods are selected to separate the period before the introduction of the SE fee, and to 
allow a full decade of completed filing cohorts for the last period – although this period looks longer, there 
are long delays in processing some patents and for most of the later file years only a small proportion of 
filings have completed the examination process.  
                                                 
21
 While missing firm size data are more prevalent in the earliest period, this pattern seems unlikely to be 
attributable simply to the assignment process for missing data, as it is consistent with the general pattern of 
falling share of smaller firms among patent applicants. 
22
 Blind and colleagues usefully summarise the evidence refuting the theoretical position that patents should 
be more important for small than for large firms before adding their own data showing that patenting is 
more important and frequent among large than among smaller firms in Germany (Blind et al., 2006: 661-2). 
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3.4 Technology field 
There are well-known challenges in identifying the technology field of patents, 
particularly if one is interested in the industrial use of the technology (Griliches, 1990). 
Nonetheless it is of interest to review at least the broad technology fields in which 
Australian owned US patents are found. The focus is on the technology in which the firm 
is operating. If all patents owned by a firm are classified in a single category (mechanical, 
electrical or chemical) then the firm is classified in that technology field.23 However, if 
the firm holds patents across more than one category it is classified as ‘mixed’ in terms of 
its technology field. Over time the proportion of firms patenting in the mechanical arena 
has declined, though this is still the dominant group of firms (Table 5). The shares of 
firms patenting in both the chemical and electrical arenas have increased, in both cases 
most significantly in the period since 1995. The increase over time in those firms 
patenting across more than one broad technology field occurred between 1984 and 1994 
in contrast to the increase in chemical and electronic patenting after 1994.  
Table 5: Firms’ field of technology by period last patented 
Technology 
field of firm 
 
Year last granted patent filed 
to end 1984 1985-1994 1995 on Total 
N % N % N % N % 
mechanical 295 69% 556 65% 1126 53% 1977 58% 
chemical 75 18% 141 17% 456 21% 672 20% 
electrical 33 8% 80 9% 343 16% 456 13% 
mixed 25 6% 73 9% 198 9% 296 9% 
 428 100% 850 100% 2123 100% 3401 100% 
 
Smaller firms are more likely to be patenting in mechanical fields than are larger firms 
(Table 6). There is only a small difference in the proportions of smaller and larger firms 
patenting in either the chemical or electrical areas, but larger firms are – as one might 
expect – more likely to be patenting across more than one broad technology field. 
  
Table 6: Firms’ field of technology by firm size 
Technology field of 
firm 
 
Firm size 
Small firms Large firms Total 
N % N % N % 
mechanical 1604 62% 371 46% 1977 58% 
chemical 489 19% 182 22% 672 20% 
electrical 336 13% 119 15% 456 13% 
mixed 153 6% 138 17% 296 9% 
Total 2582 100% 810 100% 3401 100% 
Notes:  Nine firms are known to have ceased operations and are included only in the total count. 
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 For details of the US patent codes assigned to each technology field see Kingston and Scally, 2006, 
Appendix B (pp. 181-7). 
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4.  Insights into Australian innovative firms 
Can these data be used to develop any meaningful insights into leading Australian 
innovative firms?  
The dataset is dominated by firms who have only once gained a US patent. While some 
of these may go on to acquire further such patents, they can hardly be called technology 
leaders. Some of these 2,256 firms may be beginning a path of significant innovation, but 
the simple acquisition of one US patent does not in itself indicate this. After all, the level 
of inventiveness required for gaining a US patent is more akin to ‘marginal difference 
from existing’ than to ‘genuine and at least modest advance’ (see, for example, Lunney, 
2001). A further 548 firms own two US patents but, as shown in Section 4.1 below, many 
of these are likely to have made only a single innovation. These findings parallel those 
reported by Macdonald in respect of small British firms acquiring UK patents – most 
firms with one patent in 1990 had acquired a second patent, but only 13 percent had more 
than 10 patents (Macdonald, 2003).  
At the other extreme is Silverbrook with its several thousand US patents. This case, and 
the lessons it provides is considered below (Section 4.2). 
But the most fruitful area for looking for insights to guide Australian innovation policy is 
among firms with two or more US patents, particularly among the small set of 224 firms 
which own six or more US patents (see Section 4.3 below).  
4.1 Firms with two US patents 
Another question that arises in attempting to identify groupings of innovative firms is 
whether those with two US patents have two genuinely different inventions, or whether 
these are closely related. In the domestic environment firms usually take advantage of the 
provisional system to lodge an initial then a final application. This is less likely to apply 
for overseas filings, but is nonetheless a possibility. For the 548 firms with two US 
patents, titles were scrutinised for similarity. Titles were absolutely identical in 20 
percent of cases, and in a quarter of these cases the two patents were filed within a period 
of one or two years.24 A further 31 percent of firms have very similar titles, and of these 
two-thirds were filed within two years of each other. Overall among the firms with two 
US patents over half (58 percent) involved patents filed within two years of each other. 
These firms may be very like those firms with only one US patent – their experience of 
US patenting covers a narrow range of years and a narrow technology specialisation.25   
A minority of firms filed their two patents at least 5 years apart: 18 per cent where titles 
were similar and 22 per cent where titles differed. Such firms may well have produced a 
genuine advance on their initial innovation. Overall 18 per cent of these firms filed five 
or more years apart and just six per cent filed ten or more years apart. 
                                                 
24
 That is, filed in the same calendar year or in two consecutive calendar years. For another 30 of these 113 
firms the two patents were filed not more than two years apart, giving a total of 52 percent of where file 
dates were within two years.  
25
 Some of the identically titled and closely filed patents may be for different inventions, but equally they 
may be simple variations on the theme, or extremely minor modifications. The US does have a system of 
terminal disclaimers where the subject matter of a second application very largely overlaps that of an 
earlier application, but summary data on this is not included in the BIB bibliographic information.  
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4.2 Silverbrook: an outlier or a model? 
This firm commenced patenting in the USA in 1998, when it claimed the SE fee for 63 of 
the 158 applications filed (Table 7). The percentage where the SE fee was claimed 
increased to 58 percent in 1999 before falling to 47 percent in 2000, then 20 percent in 
2001. Since 2005 Silverbrook has not claimed the SE fee for any of its applications. It 
seems likely that Silverbrook passed the size qualifier for the SE fee in the early 2000s, 
when it owned some 760 granted US patents. While little is known about the financing of 
this privately owned company, it is less secretive about its patenting activities. Its website 
provides information about its patenting experience and takes pride in the large number 
of patents owned. Silverbrook employs a number of in-house patent attorneys, and some 
of these attend general conferences on patenting. Their target output is one patent 
application a day per attorney.26 The company, founded in 1994, undertakes research on 
small high-speed printers under the registered trade mark Memjet.27  
Table 7: The Silverbrook experience: US patent applications and grants 
 USPTO “BIB” data USPTO PatFT and APPFT data*  
File 
year 
# SE 
fees 
# 
grants 
% with 
SE fees 
applications 
pending 
from year’s 
filings  
grants 
from 
year’s 
filings 
total 
filings 
% of 
cohort 
granted to 
date 
1998 63 158 40% 0 157 157 100% 
1999 19 33 58% 0 33 33 100% 
2000 110 236 47% 0 235 235 100% 
2001 16 82 20% 11 82 93 88% 
2002 65 254 26% 0 253 253 100% 
2003 1 341 0% 160 341 501 68% 
2004 1 731 0% 331 736 1067 69% 
2005 
 595 0% 572 612 1184 52% 
2006 
 338 0% 378 347 725 48% 
2007 
 404 0% 512 429 941 46% 
2008 
 415 0% 915 548 1463 37% 
2009 
 73 0% 494 214 708 30% 
2010 
 6 0% 490 72 562 13% 
Notes: * The PatFT (granted patents database) and AppFT (published applications) databases can be 
found at http://patft.uspto.gov/  These databases were searched with a query to identify Silverbrook as the 
assignee and the year of filing (e.g. “AN/Silverbrook AND APD/1/1/2010->12/31/2010”). The resulting 
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 Personal discussion with Silverbrook patent attorney at a workshop on commercialising inventions 
(Melbourne, February 2009). 
27
 http://www.silverbrookresearch.com/l-en/technology.html. The company website speaks more generally 
about Silverbrook as an “independent contract research and development company” 
(http://www.silverbrookresearch.com/l-en/faqs.html), and notes that the Memjet printers are produced by 
licensed “international companies” (http://www.silverbrookresearch.com/l-en/index.html). However there 
is no indication on the website of any other area of technology development. While earlier versions of their 
website provided details of their many patents, this information has now been moved to the separate 
Memjet website (http://www.memjet.com/technology/patents_research/) (Moir, 2008: 292-3). The Memjet 
website refers to Silverbrook as “a private, independent R&D company based near Sydney, Australia. The 
company is responsible for designing and developing the core Memjet technologies and components. 
Silverbrook Research also qualifies component manufacturers and high-volume manufacturing processes 
and equipment.” (http://www.memjet.com/partners/value-chain/).  
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figures can be added to gain total filings each year and calculate the percentage of each year’s filings which 
have been granted as at 14 June 2011. While the published applications database excludes applications with 
no overseas parallel, this is unlikely to apply to Silverbrook which also takes out many patents in Australia 
and Europe. 
Gans and Hayes have noted that Australia’s apparent increase in ‘technological 
specialisation’ is largely due to Silverbrook’s US patenting activities, and they note that: 
“While many Silverbrook patents appear to focus on small-format photo 
printing and mobile phone printing, the company’s initial foray [into 
commercialisation] is instead targeting fast letter printing using a fixed print 
head that spans the width of the page and contains a very high number of 
nozzles.”  (Gans & Hayes, 2010: 11) 
The Silverbrook data throw light on the extent to which filing cohorts are processed 
within a particular time. For the early filings – from 1998 to 2002 – most applications 
have been fully processed. However from 2006 on less than 50 per cent had been 
processed as at 14 June 2011, and for 2003 to 2005 between 31 and 48 percent remained 
pending (Table 7). As Griliches clearly pointed out in 1990,28 it is not sensible to use 
patent data by grant year because of the impact of administrative changes. At the same 
time the more valid patent data by filing year can be some five to eight years out of date.  
Silverbrook operates in that area of complex electronics where strategic patenting is rife 
(Bessen, 2003, Hall, 2005, Hall & Ziedonis, 2001), or, as one of their patent attorneys put 
it to me “we need to swap truckloads of patents”. A review of some of their patents 
shows how trivial many of them are. These trivial patents are likely to surround and hide 
the core of their useful technology. Very trivial patents include such titles as Classifying 
an input character, Shopping system having user interactive identity and product items, 
Method and system for capturing a note-taking session, Method of configuring a printer 
for vacation periods, Method and system for instruction of a computer using coded 
marks, Method and system for providing insurance services and Method and system for 
accessing travel services. 
The implications of this case for the analysis of patent data are significant – as shown in 
Figure 5, the whole Australian experience of patenting in the USA is changed by the 
behaviour of one company. Without Silverbrook the trend and volume of Australian 
patenting in the USA would be lower. Patent data are frequently used in high-volume 
quantitative analyses, where the impact of such idiosyncratic factors can easily be missed.  
4.3 Firms patenting often in the USA 
Having set aside those firms which assign all patents to overseas entities, those which 
have only one or two US patents, and the extreme outlier Silverbrook with its many 
thousands of patents, there remains a group of 597 firms with between three and 400 US 
patents. This divides into a set of 373 companies with just a handful of US patents (three 
to five), and 224 firms with at least six but less than 400. Of the 597 firms, 450 have at 
least one granted US patent in the most recent period (1995 or later). The remainder of 
the paper focuses on these 450 firms. Of these firms 37 are overseas based, four are 
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 Griliches:1990: 1690-3.  
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companies where at least some patents are jointly owned by an Australian and an 
overseas assignee, and the remaining 409 are based in Australia. 
The 37 overseas based companies are generally large global patenters. The dominant 
industry is electronics and software, with majors such as Canon (376),29 Cisco (119) and 
Alcatel (103) as well as speciality companies such as games software company Konami 
(8). Increasingly firms operating in the automotive and other engineering-based industries 
incorporate electronics into their core technology, and such firms are well represented – 
Schefenacker Vision (37) has a core capability in car mirrors but also produces electronic 
components, Illinois Tools (23) is increasingly diversified and Weir Warman (34) 
produces equipment for the mining industry. Another major area represented is 
chemicals, including pharmaceuticals.30 Finally there are two packaging companies 
(Precision Valve Corporation (6) and Tetra Pak (4)). One outlier among these firms – 
Multistack Inc. – was a management buy-out focusing on the US distribution of 
Australian designed water chillers. As such it is clearly a spin-out from indigenous 
Australian inventive activity, but the company and its sales is overseas based. The 
company website indicates recent commencement of manufacturing in the USA.31 
Are the remaining set of 409 Australian based companies the core of leading innovation 
in Australia? There are 268 small and 141 large companies, so large companies are more 
frequent than in the general dataset of US patent holders. As one might expect the smaller 
firms hold fewer US patents – 90 percent have five or less and only ten percent more than 
ten, compared to 48 percent and 52 percent among large firms. As in the larger dataset, 
smaller firms are more likely to be operating in mechanical technologies (38 compared to 
33 percent) than larger firms and are less likely to be patenting across technology fields 
(26 compared to 38 percent).  
Those with more than 25 US patents during the period are shown in Table 8. As one 
would expect, this group of companies includes some very well known Australian firms 
which have been successful in developing and globally marketing leading edge 
technology. Such firms include ResMed, Orbital, Cochlear and Aristocrat.32 There are 
also two major companies that have developed out of the Australian subsidiary of ICI.33 
Also included are well-known companies with a strong R&D competence, but operating 
in industries where R&D is not as dominant an activity as in medicine.34 Two 
independent companies are now owned by overseas companies – Bishop Steering and 
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 The figures in parentheses are the number of patents in the dataset owned by the specified company. 
30
 Johnson & Johnson (32), Du Pont (28), Chiron (20 – now owned by Novartis), Dow Corning (11) and 
Intervet and Monsanto in the agricultural chemical arena (10 and 7). 
31
 http://www.multistack.com/about/default.aspx  Beyond this information there is no link on the website 
back to the original Australian company. Further there is no indication of a continued relationship, with 
Multistack Inc claiming itself to be a leading innovator not an imitator.  
32
 Another well-known Australian company fitting this designation is Gene Shears, which has only 24 US 
patents so does not fit the criteria for Table 8. Gene Shears is a spin-out from CSIRO, the major publicly-
funded research institute in Australia. It is an unlisted company and while information is available on the 
original technological invention, it is difficult to obtain information about its performance. As a subsidiary 
of CSIRO, Gene Shears is a small company. It has never, however, claimed the SE fee for its US patents. 
33
 http://www.orica.com/BUSINESS/COR/orica/COR00254.nsf/Page/About_OricaHistory  
34
 It is notable that these companies are dominated by mining – BHP and Rio Tinto are major players in 
diversified mining activities and James Hardie is a fibre cement maker. But this groups also includes 
Telstra – a telecommunications service company.  
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Mount Isa Mines (MIM). Finally there are two companies about which no useful 
information can be found.35  
Technology-led successes 
Australia has a number of successful start-ups in medical technology and pharmaceuticals 
and several of these feature in this dataset.  
Table 8: Australian-based companies, last patenting since 1994, with >25 US patents  
Company 
# US 
patents Size 
Tech field Assign-
ment 
Fee 
strategy 
Technology-led success stories 
  
   
ResMed 216 L mixed All AU change 
Orbital 125 L mechanical All AU na 
Cochlear 85 L mixed All AU change 
Aristocrat 77 L mechanical All AU na 
AMRAD (Zenyth) [now Merck] 45 S chemical All AU mixed 
CSL  42 L chemical All AU na 
F. F. Seeley 42 S mixed All AU mixed 
Biotech Australia [now 3M] 39 L chemical All AU na 
Memtec 34 L chemical mixed no 
Metal Storm 33 S mechanical All AU mixed 
Arana Therapeutics [now Cephalon] 31 S chemical All AU c 
AMBRI 26 L chemical All AU na 
Australian offshoots of global companies 
   
Orica 265 L mixed mixed na 
Dulux Australia 35 L chemical All AU na 
Large Australian companies 
     
BHP 166 L mixed All AU na 
Rio Tinto 72 L mixed All AU error 
Telstra 46 L mixed All AU na 
James Hardie 44 L mixed mixed na 
Amcor 34 L mixed All AU na 
Bluescope Steel 27+25.5 L mixed mixed na 
Australian companies taken over by overseas companies 
  
Bishop Steering  51 L mixed All AU na 
Mount Isa Mines (Xstrata) 28 L mixed All AU na 
Other 
     
Technological Resources 88 L mixed All AU na 
Kinetic 25 S mixed All AU mixed 
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 Kinetic Limited has 25 US patents in the area of vehicle suspension systems, filed 1993 to 2005. 
Technological Resources has 88 patents filed 1993 to 2009 in the minerals/minerals processing area. Partly 
because of their names it has not been possible to find information about them except about their patents. 
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ResMed was a 1989 start-up based on technology developed at the University of Sydney 
for a device for treating obstructive sleep apnoea.36 It now has 216 US patents and 84 
registered trade marks. ResMed would have benefited substantially from R&D grants and 
tax concessions in its early years. In its early years it sought the SE fee for its US patents, 
but has not done this since 1998. While still listed on the Australian stock exchange, it is 
also now listed on the New York Stock exchange and has moved its investor information 
from its Australian to its US website. It now has over 3,000 employees, about a third 
located in Australia.37 ResMed has more granted patents in the USA than in Australia.38 
Cochlear has a similar story – it filed its first US patent in 1985 and claimed the SE fee 
for all patents filed before 1999. During its early years Cochlear benefited substantially 
from Australian government R&D support programs, and use of this support continues 
today.39 By 2010 Cochlear was reporting 2,239 employees worldwide, and reinvestment 
of 13 percent of its revenue in R&D. Cochlear recognises the importance of patents and 
in its 2010 report noted that it had more than 850 patents pending or granted worldwide. 
Much of Cochlear’s manufacturing and R&D activities remain in Australia though it also 
manufactures in Sweden.40  
Arana Therapeutics41 was a small Australian company operating in the antibody 
therapeutics sector.42 Arana had licensing agreements with a number of major 
pharmaceutical companies and when it was acquired by US-based Cephalon in 2009, 
Cephalon advised that it anticipated those royalties would offset the costs of development 
in the near term.43. At the time of acquisition Cephalon announced it anticipated 
advancing Arana’s pipeline of products in inflammatory diseases and cancer. It is not 
possible from Cephalon’s website to establish whether the Arana facility in NSW still 
exists following the purchase, though Cephalon does maintain an Australian subsidiary.44 
Over the period 1993 to 2007 Arana acquired 31 US patents. While it remained small (70 
employees) until its acquisition by Cephalon, Arana had a mixed strategy of claiming the 
SE fee, and ceased doing so only in 2001. This may have been because of its licensing 
agreements with major players such as Abbott Laboratories and Johnson & Johnson.  
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 http://www.resmed.com/uk/about_us/history.html?nc=aboutus 
37
 “As of June 30, 2010, we had approximately 3,200 employees or full time consultants, of which … 400 
in research and development… Of our employees and consultants, approximately, 1,300 were located in 
Australia…” ResMed 2010 Annual Report (http://investor.resmed.com/phoenix.zhtml?c=70291&p=irol-
reportsAnnual).  
38
 A search of AusPat on 5 July 2011 shows ResMed has 191 Australian patents which have ever been 
accepted or sealed (of which 62 have lapsed or ceased).  
39
 Unfortunately the Australian government does not make public the amount of R&D support provided to 
companies nor who the beneficiaries are. Likewise companies do not provide information on this in their 
annual reports. Even the government’s major 1995 enquiry into R&D support programs provided only very 
rules-based information on R&D support, with no information on specific beneficiaries (Productivity 
Commission, 1995). 
40
 http://www.cochlear.com/corporate/annual-reports 
41
 Previously named Peptech Limited and Peptide Technology Limited 
42
 http://www.biotechnology.nsw.gov.au/sectors.aspx?sectorid=7&companyid=1645.  
43
 http://investors.cephalon.com/phoenix.zhtml?c=81709&p=irol-newsArticle&ID=1290449&highlight 
44
 Cephalon itself was only founded in 1987 but is now a large (3,000 employee) company which is a 
member of both Fortune 1000 and the S&P 500 Index 
(http://investors.cephalon.com/phoenix.zhtml?c=81709&p=irol-newsArticle&ID=1290449&highlight= ). 
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Like ResMed, Cochlear and Arana, AMRAD (now Zenyth)45 is one of Australia’s medical 
research success stories. This small company was formed by four leading edge medical 
research institutes in 1986, but was delisted from the Australian Stock Exchange in 2006 
following its take-over by CSL.46 It was subsequently sold off to Merck. CSL itself is a 
rather different story from ResMed, Cochlear and AMRAD – it originated in the 
privatisation of a government vaccines and serum facility. The privatised CSL has 
performed well, and as noted here has expanded through take-overs of successful start-
ups like AMRAD as well as organic growth.  
Orbital is an interesting innovation story, perhaps not well known outside Australia. 
Orbital’s basic technology is disruptive, and the firm faced many challenges in trying to 
commercialise its inventions. The initial orbital engine used only one triangular shaped 
piston to create five combustion chambers, and attracted substantial interest and support. 
In the end, however, the technology was unable to compete against normal car engines. 
However application of the sophisticated fuel-injection and combustion system 
developed for the orbital engine to two-stroke engines was commercially successful.47  
Aristocrat is also very different – it produces gambling machines, originally specialising 
in slot machines (better known as ‘one-arm bandits’ or ‘fruit machines’). Aristocrat has 
had a roller-coaster ride in terms of its performance as a company, though it ranks second 
globally in the slot machine line of business.48 Aristocrat has expanded from its slot 
machine base into software games, so can be considered to be part of the electronics and 
computing sector.  
The Australian Membrane and Biotechnology Research Institute (AMBRI) was associated 
with the University of Sydney, and was registered as Australian Membrane Technologies 
Pty Limited. According to NSW government information, the company was established 
“to commercialise a novel nano-particulate membrane bioreactor technology (the 
"NMB") with a wide range of applications, in particular, waste water treatment and 
recycling.” The central technology is a membrane which efficiently aerates organic 
matter in waste streams. The company was granted 26 US patents filed between 1991 and 
2001. It appears, however, that the company no longer exists, and as it was privately held 
public sources on take-overs do not indicate its fate.49 
Memtec was an Australian start-up – a spin-out from the University of New South Wales 
– which made use of government R&D grants in its early years. The original patent was 
taken out by UNSW covering an innovative polyamide low pressure filtration membrane. 
It became a public company in 1983 and listed on the ASX in 1984. One of its patent 
attorneys provided evidence to an Australian parliamentary committee in 2005 
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 Acronym for Australian Medical Research and Development Consortium Limited. It changed its name to 
Zenyth Therapeutics in 2005 (http://www.eoas.info/biogs/A002012b.htm). 
46
 http://www.delisted.com.au/Company/9490  
47
 http://www.powerhousemuseum.com/australia_innovates/?behaviour=view_article&Section_id=1020&article_id=10041 
48
  http://en.wikipedia.org/wiki/Aristocrat_Leisure   
49
 Links from the NSW government site (http://www.biotechnology.nsw.gov.au/alphabetical.aspx?  
letter=a&companyid=1698) to the company no longer work. No information could be found on the current 
University of Sydney website, except for the 2004 University of Sydney Annual Report where its name is 
given in a list of centres. The Australian Department of Foreign Affairs and Trade gives publicity to AMBRI 
in the context of nano-technology to be used for biosensors, but provides no links to the source material 
(http://www.dfat.gov.au/facts/sci_achv.html).   
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suggesting, inter alia, that take-up of this new technology in Australia was poor.50 
Memtec established a US subsidiary and in early 1998 was taken over by US-based Pall 
Corporation.51 All patents filed from 1984 to early 1995 are assigned to the Australian 
Memtec entity, but from May 1995 the remaining four patents are assigned to Memtec’s 
US subsidiary. Memtec never claimed the SE fee. No Australian-invented US patents 
have been granted from filings since mid 1996. This suggests that the R&D expertise 
located in Sydney has either moved to the new US venue or has been disbanded 
following take-over by Pall Corporation. The word Memtec is not on the Pall Corporation 
website.52 No Pall Corporation US patents with an Australian inventor could be found. 
Biotech Australia undertook much of its R&D jointly with universities and/or CSIRO. Its 
core technology, released in 1990, was an innovative screening test for detecting 
Salmonella which substantially reduced the waiting period for results. It was 
manufactured and marketed worldwide by Biotech's Tecra Diagnostics division. It won 
the 1992 Australian Food Industry Innovation Award. Subsequently the company 
launched a test for Listeria in food.53 Little information is available on the change from 
Biotech to Tecra International as this was a private buy-out by management. Tecra 
became part of the Biotrace International Group in 2004 and was then acquired by 3M in 
late 2006. Tecra continues to manufacture rapid test kits for major causes of food borne 
illness as well as test kits for toxins and allergens.54 
Seeley International (F. F. Seeley Nominees) has 42 US patents acquired between 1982 
and 2009. Ten of its 42 US patents are defined as chemical though they concern 
evaporative cooler systems and fire retardants; four are defined as electrical, concerning 
switches and leads; and the remaining 28 are mechanical, again largely in the area of 
evaporative coolers. Originating in Adelaide in 1972, after developing an all-plastic 
evaporative air conditioner, Seeley began exporting in the 1980s. In the 1990s Seeley 
acquired Braemar, Coolair and Tudor, expanding its product range to heating and 
cooktops. Seeley International remains a small enterprise, employing just 300 people.55 It 
has claimed the SE fee on all but two of its US patents.  
Metal Storm, founded in 1994, was based on the development of technology allowing 
stacking of rounds for weapon systems. It listed on the ASX in 1999 expanding to take on 
US government contracts. The company owns 33 US patents filed between 1998 and 
2008. It has sought the SE fee on just four of these. In Australia it has filed 57 standard 
patent applications in the period since 1994, and 13 of these are currently in force, 
including the original “a barrel assembly”.  
Of these 12 companies which grew from small beginnings on the back of solid 
technological innovation, five are in the medical area. The others are quite diverse in 
terms of their technology. Seven are now classified as large companies, though some 
became large as a result of being taken over. Three of the twelve companies are now 
owned by overseas entities. The meaning of this change of ownership for the location of 
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their leading edge R&D activities is unclear. At least half of these companies have 
commenced from research undertaken in universities or research institutes. 
Offshoots of overseas companies 
Originally the Australian subsidiary of ICI,56 a major UK chemicals company, Orica was 
spun off in 1997 when it changed its name. It divested its Dulux paint interests to focus 
on services to the mining, construction and infrastructure industries. Between 1971 and 
2007 it acquired 265 US patents. The great majority of these were assigned to its 
Australian entity, with just 12 percent assigned to the British parent company. The 
chemical industry involves substantial teamwork in research. Among the 234 patents 
assigned to the Australian subsidiary just 14 involve non-Australian residents in the 
research team. But among the 31 assigned to the UK, 25 involve non-Australian 
inventors. This suggests that the location of the research activity of those patents assigned 
overseas may well have been overseas, with some subsequent movement of research 
staff. As noted, Dulux Australia was part of ICI’s Australian subsidiary but after this 
became independent, the Dulux Group was spun out as a separate company. Dulux 
Australia includes Balm Paints which started in Sydney in 1918.  
Large Australian companies 
BHP – “the Big Australian” – remains an iconic Australian company despite its 2001 
merger with Billiton to become the global resource giant BHP Billiton. It remains listed 
on the ASX with the code BHP, with a secondary listing on the London stock exchange. 
Since 1972 BHP has obtained at least one US patent every year, with the latest issued 
patents being five granted from filings in 2007. This contrasts with another large 
Australian metals company, Bluescope Steel. Bluescope was formerly a business division 
of BHP and has produced several important inventions including Colorbond in 1966; a 
zinc-aluminium product developed in the mid 1970s jointly with a US steel company and 
a thin strip casting process developed in partnership with Ishikawajima-Harima Heavy 
Industries of Japan.57 This dataset includes 51 jointly owned Bluescope/Ishikawajima 
patents as well as the 27 owned by Bluescope. Indeed all Bluescope US patents since 
1993 and jointly owned with Ishikawajima. While Bluescope has a number of significant 
innovations, as a smaller company it patents less frequently than BHP. 
Rio Tinto is another diversified resource giant whose major operations are in Australia 
and Canada. It has headquarters in London and Melbourne. Like its rival BHP, Rio has 
dual stock exchange listing in both the UK and Australia.58 While BHP has 165 US 
patents filed in the period 1972 to 2007, Rio has 72 filed in the period 1973 to 2001. 
Either subsequent filings from Rio are very delayed at the USPTO or Rio has ceased 
actively patenting in the USA, at least where Australian resident inventors are concerned. 
Both companies patent across a range of technology classes though Rio’s patents are 
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more heavily concentrated in the chemicals area (three-quarters) while BHP has just over 
40 per cent in each of chemicals and mechanics and the remaining in electrical areas.  
The third resource-based company here is James Hardie, a fibre cement manufacturer. 
This company is unusual in that is has moved its headquarters twice after a very long 
period as a major established Australian company. Its strong Australian base remains 
evident in the fact that it is still listed on the ASX. The first move – in 2001 to the 
Netherlands – occurred following legal action on behalf of former employees regarding 
asbestos-related occupational injuries. In 2010 James Hardie moved its headquarters to 
Ireland. These moves are possible because James Hardie makes substantial use of the 
parent/subsidiary company structure option. The assignment of nationality in its patent 
holdings largely follows these corporate headquarter relocations: all patents filed before 
2000 are assigned to an Australian subsidiary, all patents filed since 2005 are assigned to 
an Irish entity, and all filings between 2001 and 2004 patents are assigned to either 
Australian, Dutch or Irish entities. It seems probable that all future James Hardie patents 
will be assigned to their Irish entity.  
Telstra is the privatised Australian phone company comprising former publicly owned 
domestic and overseas telecommunications companies. Because of this base it remains 
dominant in the Australian landline market as the original competitor had as its core only 
the small satellite company AUSSAT. Other companies have made more substantial 
inroads into the mobile market which is much more competitive than the landline market. 
Seventeen of Telstra’s 46 US patents date from the pre-1993 public ownership period.  
Amcor is a major Australian pulp and paper manufacturer operating in the global 
packaging industry, like its rival the privately owned Visy. It is now among the global top 
1,000 companies.59 Amcor owns 34 US patents obtained in the period 1974 to 2003. This 
is substantially more than the ten owned by Visy.  
Australian companies taken over by overseas companies 
As noted above a number of companies discussed under the heading of technology-led 
success stories have been taken over by overseas company – AMRAD by Merck, Biotech 
Australia by 3M, Memtec by Pall Corporation and Arana Therapeutics by Cephalon.60 
Two rather larger Australian companies have had similar experiences – Bishop Steering 
and Mount Isa Mines (MIM). MIM was taken over by Xstrata in 2003, a take-over which 
led to Xstrata doubling in size. Of the patents in the dataset now owned by Xstrata, 23 out 
of 28 are in the name of Mount Isa Mines.61 
In early 2011 Bishop Steering was taken over by Georgsmarienhütte Group.62  As the 
name implies, Bishop’s speciality is vehicle steering systems, and it acquired 51 US 
patents in the period 1988 to 2005. According to the press release issued by its new 
owner, Bishop actively licensed its technology to manufacturers of steering gears and 
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components: “BISHOP has over 250 patents and patent applications in 17 countries as 
well as numerous licensees worldwide.” At the time of the takeover the Bishop 
companies in Australia, the USA and Germany employed 16 engineers and 30 production 
staff. This suggests the Australian operations are small but highly technical. 
Overall picture 
Genuinely Australian companies which actively use the US patent system are clearly a 
very diverse set. While attention here has focused on those companies making more 
frequent use of the US patent system, the diversity among those with somewhat fewer US 
patents is also striking – they too cover a very wide range of industries and firm sizes. 
The development of commercially valuable new technology has occurred across a wide 
range of products and technologies, and while university and research institute spin-outs 
do feature they are not by any means the major pattern for such innovative companies. 
Beyond that, with the data available from this particular source, and the lack of any clear 
identifier for cross-matching data to other sources, it is not possible to develop a useful 
typology of innovative firms. Nonetheless some pointers suggest useful lines of study for 
innovation policy purposes. For example, to what extent is it relevant to policy makers if 
innovative local firms are sold to overseas owners? Does this matter only if a 
consequence is the subsequent move of R&D activity or high-technology manufacturing? 
As seen here, some innovative firms can be sold more than once, for example Sola and 
AMRAD. Where innovative domestic firms grow substantially, as for example in the case 
of ResMed or Cochlear, does the company base ‘stick’ in Australia, or might it in fact 
make the move overseas?  
5. Conclusions and next steps 
5.1 Data issues  
This analysis presented in this paper shows that it is possible to use the USPTO BIB data 
series to investigate firm ownership of patents on a national basis. However the data are 
quite ‘dirty’ for this purpose and require substantial scrutiny and cleaning. Though 
tedious, this provides rewards in terms of a deeper understanding of the complexity and 
nuances of using patent data as a simple indicator of anything to do with technology.  
There are several small changes that would substantially increase the ease of use of these 
data without detracting from their richness. The first and simplest would be for the 
USPTO to recognise the reality and importance of the assignee variable and include more 
elements from this – particularly country code – in the dataset they sell. The assignee 
country code is very important for policy research purposes.  
As noted above there are reasons to believe that the inventor country code is a mix of 
residence at time of grant and residence at time of filing. The latter is likely to provide a 
solid and meaningful picture of the location of patentable inventive activity at any point 
in time. It can therefore be useful for industry and technology policy advisors. However, 
country of residence of an inventor at the time of grant – given that between two and 
seven years are likely to have elapsed – is a rather confused variable. It might be of use at 
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the instant of grant, providing a snapshot then of where past inventors are currently 
located. But the meaning of such data will not survive over time.  
In their earlier analysis Kingston and Scally used first listed inventor to uniquely assign 
USPTO-issued patents by country. In this analysis patents have been selected from the 
BIB database on the basis of any inventor being Australian. Among firms which assign 
some or all of their patents overseas there are a higher proportion of patents where the 
Australian inventor is not the first inventor. But overall, among the firms where any 
assignment was to an Australian entity, the first inventor was an Australian resident in 97 
per cent of cases. This contrasts with cases where all patents were assigned to non-
Australian entities where only 63 per cent of first inventors were Australian residents.  
More generally, it would be useful if patent offices across the world would recognise that 
asking for company identifier numbers is now standard practice in most government 
administration. For example the Australian Bureau of Statistics uses a company’s 
Business Number to track it through its Business Longitudinal Database.63 Such standard 
identifiers would make it easier to match data for the same company within and between 
datasets. In analysing patent data it is preferable to have information about the 
characteristics of the company so matching across datasets is an important facility. 
5.2 Innovating firms  
What can these data tell us about innovating firms? The simple answer is that, on their 
own, patent data provide only limited insights into innovative behaviour. The dataset is 
dominated by the 66 percent of firms who have only one US patent. To this group should 
be added many of the firms with two US patents where the patents either had very similar 
titles or were filed within two years of each other. If such firms are treated like one-off 
patenters, then fully 2,676 of the 3,401 firms provide little insight into globally leading 
innovation. This is not to say that these firms might not include firms which may take off. 
Certainly there are small start-ups in the list, such as Dyesol, but these are as yet still very 
much in the early phase of developing their products. This leaves just 725 firms which 
might provide insights into innovative behaviour among Australian firms. 
As noted above the variables available in a patents-only dataset are insufficient for any 
complex analysis. As an alternative those domestic firms with a reasonable degree of 
experience in patenting in the US were scrutinised and this showed a wide diversity both 
in terms of the types of companies patenting and in their subsequent business experience. 
The data show Australia’s competence in research based on the life sciences, with a 
number of notable successes, some of which have been taken over and some of which 
have remained independent. They also show that larger established firms in the resources 
and telecommunications sectors appear to be holding their own in terms of patentable 
technological developments.  
While the number of patents obtained varies considerably between these firms, there is 
one stand-out case – Silverbrook Research Pty Ltd. This company has developed very 
small high-speed printing technology, and surrounds its core technology with thousands 
of peripheral (and extremely trivial) patents. While this is unique in Australia it is 
common practice in the electronic industries with which the firm competes. As a 
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consequence this firm’s behaviour is unlikely to provide any relevant learning for firms 
in industries where there are fewer games played around the patent system. 
A final finding of interest in this Australian case is that in a medium sized economy the 
outlier behaviour of even one firm can radically affect overall national figures and their 
interpretation. Here Silverbrook, with its 3,666 US patents, has a marked effect on both 
the volume and pattern of Australian patenting in the USA. This suggests that, at least in 
Australia, US patent data as a proxy measure for technological innovation should be 
treated with great caution. 
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Acronyms 
Apparent acronyms used in this paper and not listed here are company names. 
AMBRI  The Australian Membrane and Biotechnology Research Institute 
ASIC  Australian Securities & Investments Commission 
ASX   The Australian Securities Exchange 
AUSSAT AUSSAT was the government-owned communication satellite that was sold 
to Optus to form part of the original second telecommunications operator 
when the telecommunications sector was privatised. 
CSIRO Commonwealth Scientific and Industrial Research Organisation 
MIM   Mount Isa Mines  
SE   small enterprise 
USPTO  United States Patent and Trademark Office 
AusPat available at http://www.ipaustralia.gov.au/auspat/index.htm is a searchable 
database of Australian patents 
Patent country codes 
AN Netherlands Antilles 
AU Australia 
CA Canada 
CH China 
DE Germany 
FR France 
GB United Kingdom 
HK Hong Kong 
IE Ireland 
JP Japan 
NL Netherlands 
SE Sweden 
US USA 
 
